-

CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences

CORRECTION...by Veracyte, Inc.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Details of the Raymond James Human Health Innovation Conference have been corrected.

The updated release reads:

VERACYTE TO PRESENT AT UPCOMING INVESTOR CONFERENCES

Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced that Marc Stapley, chief executive officer, and Bonnie Anderson, executive chairwoman, are scheduled to participate in two upcoming virtual investor conferences:

  • Goldman Sachs 42nd Annual Global Healthcare Conference
    Fireside chat on Wednesday, June 9, 2021, at 9:40 a.m. Eastern Time
  • Raymond James Human Health Innovation Conference
    Fireside chat on Wednesday, June 23, 2021, at 2:40 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days following the conclusion of each live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Contacts

Investor and Media Contact:
Tracy Morris
Vice President of Corporate Communications & Investor Relations
650-380-4413
tracy.morris@veracyte.com

Industry:

Veracyte, Inc.

NASDAQ:VCYT
Release Summary
Veracyte to Present at Upcoming Investor Conferences
Release Versions
English

Contacts

Investor and Media Contact:
Tracy Morris
Vice President of Corporate Communications & Investor Relations
650-380-4413
tracy.morris@veracyte.com

More News From Veracyte, Inc.

Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company’s website and will b...

Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S....

ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer...
Back to Newsroom